Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.

  • Novo Nordisk (CPSE:NOVO B) is rolling out its oral Ozempic (semaglutide) tablet across the US as the only FDA approved oral GLP-1 for adults with type 2 diabetes.

  • The company plans broad distribution through more than 70,000 US pharmacies.

  • New access partnerships with WW International and GoodRx aim to support patients through digital health tools, discounts and self pay options.

  • The launch includes a mix of insurance coverage pathways and cash pay programs targeting both insured and self paying patients.

Novo Nordisk, best known for its injectable GLP-1 drugs, is extending the Ozempic brand into an oral format that fits more easily into many patients’ daily routines. GLP-1 therapies are a key focus area in diabetes and weight related care, and a tablet option gives the company another way to reach adults with type 2 diabetes who may prefer pills over injections.

For investors looking at CPSE:NOVO B, this US launch adds another element to the Ozempic story, with a product that can be prescribed and dispensed through familiar pharmacy and digital channels. How doctors, payers and patients respond to the combination of broad pharmacy coverage and the WW International and GoodRx partnerships will be important for assessing the commercial impact over time.

Stay updated on the most important news stories for Novo Nordisk by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novo Nordisk.

CPSE:NOVO B Earnings & Revenue Growth as at May 2026 CPSE:NOVO B Earnings & Revenue Growth as at May 2026

📰 Beyond the headline: 5 risks and 4 things going right for Novo Nordisk that every investor should see.

Quick Assessment

  • ✅ Price vs Analyst Target: At DKK278.0 versus a consensus target of DKK307.7, the share price sits about 11% below analyst expectations.

  • ✅ Simply Wall St Valuation: Shares are described as trading 63.6% below estimated fair value, which is a large implied discount.

  • ✅ Recent Momentum: A 30 day return of 17.3% signals strong recent interest in the stock.

There is only one way to know the right time to buy, sell or hold Novo Nordisk. Head to Simply Wall St’s company report for the latest analysis of Novo Nordisk’s Fair Value.

Key Considerations

  • 📊 The oral Ozempic US rollout, plus digital access partnerships, gives Novo Nordisk another way to monetise its GLP 1 franchise in type 2 diabetes.

  • 📊 Watch how prescription volumes, insurance coverage patterns and uptake through WW International and GoodRx evolve relative to the current DKK278.0 price and 12.0x P/E.

  • ⚠️ A key risk is execution, including pricing, reimbursement decisions and any pressure on margins in light of the existing set of 5 flagged risks.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Novo Nordisk analysis. Alternatively, you can check out the community page for Novo Nordisk to see how other investors believe this latest news will impact the company’s narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NOVO-B.CO.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com